Objective The role of serum uric acid as an independent risk factor for cardiovascular
disease remains unclear, although hyperuricemia is associated with cardiovascular disease …

Metabolic syndrome (MetS) includes visceral obesity, hyperglycemia, dyslipidemia, and
hypertension. The prevalence of MetS is 20-25%, which is an important risk factor for chronic …

Background Long-term statin treatment reduces the frequency of cardiovascular events, but
safety and efficacy in patients with abnormal liver tests is unclear. We assessed whether …

Context: The metabolic syndrome (MetS) is a cluster of metabolic abnormalities that
increase the risk for type 2 diabetes mellitus and vascular disease. The common …

Background: Statin therapy is effective for the prevention of coronary heart disease and
stroke in patients with mild-to-moderate chronic kidney disease, but its effects in individuals …

Metabolic syndrome (MetS) is a term used to denote a combination of selected, widely
prevalent cardiovascular disease (CVD)-related risk factors. Despite the ambiguous …

AIM: To investigate the effect of rosuvastatin monotherapy on non-alcoholic steatohepatitis
(NASH). At present there is no effective treatment for non-alcoholic fatty liver disease or its …

Non-alcoholic fatty liver disease (NAFLD) is considered to be an independent
cardiovascular disease (CVD) risk factor. However, simple steatosis has a benign clinical …

The metabolic syndrome (MetS) is characterized by the presence of central obesity,
impaired glucose metabolism, dyslipidemia and hypertension. Several studies showed that …

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease (30% of the
general population) and up to 40% of cases advance to the more severe form of the disease …